Clinical Trial Update: A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of TER-2013 in solid tumors harboring AKT/PI3K/PTEN alterations is currently recruiting to assess safety and preliminary efficacy across multipl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Endometrial Cancer
• Esophageal Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Lung Squamous Cell Carcinoma
• Ovarian Cancer

Drugs mentioned

• TER-2013

Snippet

Sponsor: Terremoto Biosciences Inc. | Conditions: Breast Cancer, Endometrial Cancer | Phase 1, Phase 2 | Status: RECRUITING